News
Archive: December 2025
Financial Results for year ended 30 September 2025 and Notice of AGM
09 December 2025, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces its audited results for the year ended 30 September 2025 ("FY25").
Execution of the Group's Innovate Lead Scale strategy across the year has delivered a strong financial performance with 13% revenue growth and a 21% reduction in EBITDA loss. Commercial traction has further accelerated into FY26, resulting in a 27% increase to the order book since the FY25 year-end.
IXICO strengthens Scientific Advisory Board with two prominent global Alzheimer’s Disease and vascular experts
01 December 2025, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has appointed two leading global experts in the field of Alzheimer’s Disease (AD) and cerebrovascular disease (CVD) as advisors to the Company. Professor Michael Weiner, and Professor Joanna Wardlaw join IXICO’s advisory board with immediate effect.